Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07746232

Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study"

Sponsor: Fondazione EMN Italy Onlus

View on ClinicalTrials.gov

Summary

This is a multicenter, observational, retrospective-prospective study designed to validate the predictive role of advanced imaging in patients with newly diagnosed multiple myeloma (NDMM). The main purpose of this study is to estimate the prevalence of radiological response categories (Response Assessment Category, RAC score) and evaluate the predictive value of relative Fat Fraction (rFF%) using Diffusion-Weighted Whole-Body Magnetic Resonance Imaging (DW-MRI) in patients who have undergone autologous stem cell transplantation (ASCT) after receiving first-line anti-CD38-based quadruplet induction therapy.

Official title: Multicenter Observational Study for the Validation of the Predictive Role of Diffusion-Weighted Whole-body MRI (DW-MRI) Imaging Response According to MY-RADS Criteria (RAC Score) and Fat Fraction (rFF%) After Autologous Stem Cell Transplantation in Multiple Myeloma Patients Treated With First-Line Anti-CD38-Based Therapy (RAC-FAT Study)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

92

Start Date

2026-08

Completion Date

2030-08

Last Updated

2026-08-04

Healthy Volunteers

No

Interventions

DIAGNOSTIC_TEST

DW-MRI (MY-RADS/RAC score)

Collection and analysis of Diffusion-Weighted Whole-body MRI data performed post-ASCT. The radiological response is evaluated using the Response Assessment Category (RAC) score (1 to 5) according to MY-RADS criteria.

DIAGNOSTIC_TEST

Fat Fraction (rFF%)

Quantitative assessment of the relative Fat Fraction (percentage of fat within skeletal regions) measured on residual focal lesions after transplantation to identify functional high-risk (FHR) patients.

OTHER

Clinical Data Collection

Retrospective and prospective collection of clinical outcomes, including Progression-Free Survival (PFS), Overall Survival (OS), and Minimal Residual Disease (MRD) status from medical records.

Locations (10)

IRCCS Istituto Tumori "G. Paolo II - U.O.C. Ematologia e Terapia Cellulare

Bari, Italy

A.O.U. di Bologna - Policlinico S. Orsola Malpighi

Bologna, Italy

A.O. Spedali Civili di Brescia

Brescia, Italy

Istituto Oncologico Veneto IRCCS - UOC Oncoematologia

Castelfranco Veneto, Italy

Ospedale Classificato Valduce

Como, Italy

I.R.C.C.S. Ospedale S. Raffaele

Milan, Italy

Ospedale Niguarda

Milan, Italy

A.O.U. Maggiore della Carità

Novara, Italy

Policlinico S. Matteo Fondazione IRCCS

Pavia, Italy

ASL Roma 1

Rome, Italy